摘要
目的对晚期胃癌患者采用阿帕替尼的疗效及预后因素进行研究。方法收集病理确诊的30例晚期胃癌患者。每日口服850 mg阿帕替尼进行治疗,对临床疗效及产生的不良反应进行观察,采用Kaplan-Meier方法对患者生存进行分析。结果按照评定实体瘤临床治疗效果的标准对患者疗效评价,在疾病控制及生存受益方面,甲胎蛋白阳性胃癌患者比AFP阴性患者高,阿帕替尼治疗中产生的最主要不良反应是高血压、骨髓抑制。结论晚期胃癌患者采用阿帕替尼治疗的疾病控制及生存获益较好,能控制可能产生的不良反应。
Objective To study on the efficacy of apatinib in the treatment of advanced gastric cancer and prognostic factors. Methods The data of 30 patients with advanced gastric cancer confirmed by pathology were collected. A daily oral administration of 850 mg atapinib was performed. The clinical efficacy and adverse reactions were observed. The survival of patients was analyzed by Kaplan-Meier. Results The curative effect of patients were evaluated according to clinical tumor treatment effect evaluation entity standard, benefit in disease control and survival, AFP positive gastric cancer patients than in AFP negative patients, in most major adverse reactions of apatinib clinical treatment effects were hypertension, bone marrow suppression. Conclusion Disease control and survival benefit with apatinib in the treatment of advanced gastric cancer patients can better control of possible adverse reactions.
作者
栾丽伟
LUAN Liwei(Department of General Surgery and Oncology,People＇s Hospital of Jixi City,Jixi Heilongjiang 158100,China)
出处
《中国继续医学教育》
2018年第19期134-135,共2页
China Continuing Medical Education
关键词
阿帕替尼
晚期胃癌
化疗
预后因素
不良反应
治疗效果
apatinib
advanced gastric cancer
chemotherapy
prognosis
adverse reaction
therapeutic effect
